Infliximab use and sequential occurrence of autoantibodies and neoplasia in a patient with spondyloarthritis.
The development of antinuclear antibodies after long-term use of anti-TNF therapy has been reported by several authors. The occurrence of lymphoproliferative neoplasms and, less commonly, solid tumors has also been reported. We present a case of simultaneous development of antinuclear antibodies and solid tumor in a patient with spondyloarthritis while on infliximab therapy. The implications and possible correlations with a solid tumor occurrence are reviewed and discussed.
Hospital Abreu Sodré-AACD and Hospital Israelita Albert Einstein, São Paulo, Brazil. ricardogolmia@brturbo.com.br
Ricardo
R
Golmia
Morton
M
Scheinberg
D000328:Adult; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008159:Lumbar Vertebrae; D025241:Spondylarthritis / Q000188:drug therapy*; D013964:Thyroid Neoplasms / Q000139:chemically induced* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab